Hanlim Pharm Receives FDA Warning Letter After Aseptic Failures Found at Sterile Fill-Finish Facility

Operators breaching first air over open sterile containers, a visibly stained gown worn inside a Grade A zone, and smoke studies that failed to demonstrate unidirectional airflow protection: Hanlim Pharm Co., Ltd. is facing a formal FDA Warning Letter after inspectors documented systemic aseptic processing failures at its Gyeonggi-do, South Korea facility. The letter, issued October 2, 2026 under reference 320-27-03, cites violations of 21 CFR Parts 210 and 211 and classifies the firm's sterile drug products as adulterated under section 501(a)(2)(B) of the FD&C Act.

The April 16–24, 2026 inspection by CDER (FEI 3004886113) identified repeated first-air violations during set-up and filling operations, with personnel reaching arms, torsos, and heads directly over open sterile tubes and product-contact components. A separate observation recorded an operator in the Grade A zone wearing a visibly contaminated gown, a lapse that points to gaps in gowning qualification and real-time supervisory oversight rather than isolated human error.

The airflow findings compound the personnel failures. Dynamic airflow visualization studies showed air moving at a sharp upward angle toward return vents when barrier panels were open, leaving critical aseptic processing zones unprotected. That configuration allowed lower-classified air from the surrounding ISO 7 (Class 10,000) environment to migrate into the ISO 5 (Class 100) aseptic core, a design-level deficiency that no operator training program can fully compensate for without engineering remediation.

For QA directors and plant heads managing sterile fill-finish lines, the inspection record illustrates how smoke study deficiencies and behavioral non-conformances can reinforce each other during regulatory review. FDA's framing of the violations under 21 CFR 211.113(b), which requires validated aseptic and sterilization processes alongside written contamination-prevention procedures, signals that the agency evaluated both procedural adequacy and actual practice, not documentation alone. Hanlim's May 15, 2026 FDA 483 response was reviewed and found insufficient to close the observations.

FDA explicitly noted the Warning Letter is not an exhaustive list of violations, leaving open the possibility of additional findings. Failure to adequately remediate carries the stated risk of seizure or injunction without further notice.

The measurable remediation checkpoint will be whether Hanlim's corrective submissions demonstrate validated airflow redesign alongside documented requalification of aseptic operator behavior under conditions that replicate worst-case interventions.

Source: FDA CDER via FDA.gov Warning Letters feed, October 13, 2026. Inspection conducted April 16–24, 2026; Warning Letter dated October 2, 2026.